search
Back to results

Lung Cancer Surgery: Decisions Against Life Saving Care - The Intervention

Primary Purpose

Non-small Cell Lung Cancer

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
communication intervention
Real Time Registry and data feedback only
Sponsored by
University of North Carolina, Chapel Hill
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Non-small Cell Lung Cancer focused on measuring non small cell lung cancer, health disparities

Eligibility Criteria

21 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Age 21 years or greater;
  2. A probability of 60% or higher of a lung lesion being malignant as calculated by a Bayesian algorithm using clinical and radiographic characteristics or biopsy proven disease; and
  3. The patient has been clinically classified as having stage I or II disease.

Exclusion Criteria:

  1. incarceration / ward of the state status,
  2. Severe cognitive impairment. If a patient meets the inclusion criteria but is consistently unable to comprehend survey questions during the interview process, we will exclude that patient from the overall study.
  3. absolute contraindications by pulmonary function testing (FEV-1 < 25% of predicted)
  4. Non-English speaking. Hispanic patients represent less than 4 percent of lung cancer patients in North Carolina restricting our ability to document an intervention effect.

Sites / Locations

  • The University of North Carolina at Chapel Hill

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Communication Intervention

Real Time Registry and data feedback only

Arm Description

Specially trained communicator addresses factual understanding and elicits other barriers to care

Patients are enrolled in registry and clinicians receive warnings about delayed or missed care.

Outcomes

Primary Outcome Measures

Number of patients with stage I and II, non-small cell lung cancer who receive surgery.
The primary outcome variable, surgery yes or no, will be compared in the control group randomized to usual care, to the intervention group randomized to the cancer communicator.

Secondary Outcome Measures

Full Information

First Posted
September 11, 2012
Last Updated
October 11, 2017
Sponsor
University of North Carolina, Chapel Hill
Collaborators
East Carolina University, University of South Carolina
search

1. Study Identification

Unique Protocol Identification Number
NCT01687738
Brief Title
Lung Cancer Surgery: Decisions Against Life Saving Care - The Intervention
Official Title
Lung Cancer Surgery: Decisions Against Life Saving Care - The Intervention
Study Type
Interventional

2. Study Status

Record Verification Date
October 2017
Overall Recruitment Status
Completed
Study Start Date
August 2012 (undefined)
Primary Completion Date
June 30, 2017 (Actual)
Study Completion Date
June 30, 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of North Carolina, Chapel Hill
Collaborators
East Carolina University, University of South Carolina

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Purpose: Overall lung surgery rates and black/white disparities have not improved during a decade of documentation. The goal of this study is to incorporate lessons from the previous prospective cohort study to optimize lung cancer surgery rates and narrow black-white disparities for patients diagnosed with stage I or II, non-small cell lung cancer. Participants: Stage I and II, non-small cell lung cancer at 3 participating sites. Procedures: Phase I of the study has been completed. Phase I was a deidentified 3-year, retrospective chart review, used to establish the baseline surgical rates for the intervention. The patient enrollment phase of the study will move forward that will include use of a real time registry to follow patient progression through clinical follow up, diagnostic testing and treatment for biopsy proven or highly probable early stage, non-small cell lung cancer. The patient enrollment portion of the study will start, September 2012. All patients with Stage I or II non-small cell lung cancer who enroll in the study will be entered into real time registries at every site. Patients' progress through the registries including follow-up provider visits, diagnostic tests, and procedures will be transparent and any missed appointments will be flagged. Feedback will be given to lung cancer providers in both arms. The randomized trial will compare patients who receive usual care plus the registry to those who receive the registry plus visits and calls from a trained cancer communicator -educator (CCE) who is well versed in issues specific to lung cancer and trained in active listening and communication that accounts for patients' limitations in health literacy. The CCE will also use Kleinman's Patient Model to identify attitudes or beliefs that represent barriers to recommended care that could potentially be addressed through negotiation and more targeted communication. The hypothesis is that an electronic warning system, data transparency, and enhanced communication will optimize lung surgery rates and reduce racial gaps.
Detailed Description
Note that the registry intervention will be compared to historical controls obtained from the electronic chart review. The main outcome will be receipt of lung resection surgery and this outcome will be assessed controlling for age, race, education, income, perceptions of communication, co-morbid illnesses, and level of health literacy.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Non-small Cell Lung Cancer
Keywords
non small cell lung cancer, health disparities

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
238 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Communication Intervention
Arm Type
Experimental
Arm Description
Specially trained communicator addresses factual understanding and elicits other barriers to care
Arm Title
Real Time Registry and data feedback only
Arm Type
Experimental
Arm Description
Patients are enrolled in registry and clinicians receive warnings about delayed or missed care.
Intervention Type
Other
Intervention Name(s)
communication intervention
Intervention Description
Because of the gaps between documented outcomes of lung cancer surgery and patient communication barriers identified in our recent work, our communication intervention will focus on improving presentation of risk information and confirmation of understanding of patient medical.
Intervention Type
Other
Intervention Name(s)
Real Time Registry and data feedback only
Intervention Description
This group of patients will not received the enhanced communication intervention
Primary Outcome Measure Information:
Title
Number of patients with stage I and II, non-small cell lung cancer who receive surgery.
Description
The primary outcome variable, surgery yes or no, will be compared in the control group randomized to usual care, to the intervention group randomized to the cancer communicator.
Time Frame
Baseline to 4 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
21 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age 21 years or greater; A probability of 60% or higher of a lung lesion being malignant as calculated by a Bayesian algorithm using clinical and radiographic characteristics or biopsy proven disease; and The patient has been clinically classified as having stage I or II disease. Exclusion Criteria: incarceration / ward of the state status, Severe cognitive impairment. If a patient meets the inclusion criteria but is consistently unable to comprehend survey questions during the interview process, we will exclude that patient from the overall study. absolute contraindications by pulmonary function testing (FEV-1 < 25% of predicted) Non-English speaking. Hispanic patients represent less than 4 percent of lung cancer patients in North Carolina restricting our ability to document an intervention effect.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Samuel Cykert, MD
Organizational Affiliation
University of North Carolina, Chapel Hill
Official's Role
Principal Investigator
Facility Information:
Facility Name
The University of North Carolina at Chapel Hill
City
Chapel Hill
State/Province
North Carolina
ZIP/Postal Code
27599
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
30714689
Citation
Cykert S, Eng E, Walker P, Manning MA, Robertson LB, Arya R, Jones NS, Heron DE. A system-based intervention to reduce Black-White disparities in the treatment of early stage lung cancer: A pragmatic trial at five cancer centers. Cancer Med. 2019 Mar;8(3):1095-1102. doi: 10.1002/cam4.2005. Epub 2019 Feb 4.
Results Reference
derived

Learn more about this trial

Lung Cancer Surgery: Decisions Against Life Saving Care - The Intervention

We'll reach out to this number within 24 hrs